Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.
Authors
Sebastian Stintzing
Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Sebastian Stintzing , Josep Tabernero , Taroh Satoh , Arvind Dasari , Sara Lonardi , Cathy Eng , Rocio Garcia-Carbonero , Elena Elez , Takayuki Yoshino , Alberto F. Sobrero , James C. Yao , Stefan Kasper , Dirk Arnold , Edin Basic , Matthias Granold , Marco Petschulies , Liwen Wu , Lucy Chen , Zhao Yang , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04322539
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 116)
DOI
10.1200/JCO.2024.42.3_suppl.116
Abstract #
116
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
First Author: Yu-Xian Bai
Poster
2023 ASCO Annual Meeting
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
First Author: Arvind Dasari
Poster
2021 Gastrointestinal Cancers Symposium
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Arvind Dasari
